Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/6362
Type
ArticleCopyright
Open access
Collections
- IFF - Artigos de Periódicos [1285]
Metadata
Show full item record
UPREGULATION BY GLUCOCORTICOIDS OF RESPONSES TO EOSINOPOIETIC CYTOKINES IN BONE-MARROW FROM NORMAL AND ALLERGIC MICE
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Fernandes Figueira. Departamento de Pesquisa. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
INSERM. Unité Associeé Institut Pasteur. Uniteé de Pharmacologie Cellulaire. Paris, France.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Institut Pasteur. Station Centrale de Microscopie Électronique. Paris, France.
INSERM. Unité Associeé Institut Pasteur. Uniteé de Pharmacologie Cellulaire. Paris, France.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
INSERM. Unité Associeé Institut Pasteur. Uniteé de Pharmacologie Cellulaire. Paris, France.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Institut Pasteur. Station Centrale de Microscopie Électronique. Paris, France.
INSERM. Unité Associeé Institut Pasteur. Uniteé de Pharmacologie Cellulaire. Paris, France.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Abstract
Since the production of eosinopoietic cytokines (GM-CSF, IL-3, IL-5) is inhibited by glucocorticoids, while responsiveness to these cytokines is enhanced in bone-marrow of allergic mice, we studied the ability of glucocorticoids to modulate murine bone-marrow eosinopoiesis. Progenitor (semi-solid) and/or precursor (liquid) cultures were established from bone-marrow of: (a) normal mice; (b) ovalbumin-sensitized and challenged mice or (c) dexamethasone (1-5 mg kg(-1)) injected mice. Cultures were established with GM-CSF (2 ng ml(-1)) or IL-5 (1 ng ml(-1)), respectively, alone or associated with dexamethasone, hydrocortisone or corticosterone. Total myeloid colony numbers, frequency and size of eosinophil colonies, and numbers of eosinophil-peroxidase-positive cells were determined at day 7. In BALB/c mice, dexamethasone (10(-7) M) increased GM-CSF-stimulated myeloid colony formation (P = 0.01), as well as the frequency (P=0.01) and size (P<0.01) of eosinophil colonies. Dexamethasone (10(-7) M) alone had no effect. Dexamethasone (10(-7)-10(-10) M) increased (P<0.002) eosinophil precursor responses to IL-5. Potentiation by dexamethasone was still detectable: (a) on low density, immature, nonadherent BALB/c bone-marrow cells, (b) on bone-marrow from other strains, and (c) on cells from allergic mice. Hydrocortisone and corticosterone had similar effects. Dexamethasone administered in vivo, 24 h before bone-marrow harvest, increased subsequent progenitor responses to GM-CSF (P = 0.001) and precursor responses to IL-5 (P<0.001). These effects were blocked by RU 486 (20 mg kg(-1), orally, 2 h before dexamethasone, or added in vitro at 10 microM, P<0.001). Glucocorticoids, acting in vivo or in vitro, through glucocorticoid receptors, enhance bone-marrow eosinopoiesis in naïve and allergic mice.
Share